High Single Digit To Low Double Digits Revenue Projections For FY 25: Syngene International CEO

Watch this exclusive interview with Jonathan Hunt, CEO & MD of Syngene International, as he discusses the company's Q4 and full-year financial performance with Business Today's Sakshi Batra. In Q4FY24, Syngene saw a six percent year-on-year increase in profit after tax (before exceptional items) to Rs 189 crore, despite an eight percent decline in revenue from operations to Rs 917 crore. The EBITDA for the quarter stood at Rs 333 crore, slightly lower than the previous year's Rs 337 crore. Additionally, the acquisition of Stelis Biopharma's biologics manufacturing facility in Manufacturing Services has been successfully finalized, marking a significant milestone for the company.